无血清纯化Vero狂犬病疫苗与狂犬病人二倍体细胞疫苗(HDCV;Imovax® Rabies)在健康成人中模拟狂犬病暴露后方案接种的安全性和免疫原性比较
在美国健康成人中比较无血清纯化Vero狂犬病疫苗(PVRV-NG)与狂犬病人二倍体细胞疫苗(HDCV;Imovax® Rabies)按模拟暴露后(PEP)5剂Essen肌内方案并同时接种狂犬病免疫球蛋白(HRIG)的安全性和免疫原性非劣效性。第14天血清阳转率(RVNA滴度≥0.5 IU/mL)组间差异为-2.8%(95%CI -8.08至4.20),非劣效性未成立;两组第14天血清阳转率均<99%,未发现重大安全性问题,PVRV-NG安全性特征与HDCV相似。
要点
- PVRV-NG与HDCV第14天血清阳转率差异-2.8%(95%CI -8.08至4.20),非劣效性未成立。
- 两组第14天血清阳转率均<99%。
- 未发现重大安全性问题,PVRV-NG安全性特征与HDCV相似。
核心结论
- PVRV-NG与HDCV按模拟PEP方案并同时接种HRIG时,第14天血清阳转率差异-2.8%(95%CI -8.08至4.20),非劣效性未成立;两组第14天血清阳转率均<99%,未发现重大安全性问题,PVRV-NG安全性特征与HDCV相似。
研究设计与样本
- 在美国健康成人中开展的比较PVRV-NG与HDCV按模拟PEP方案接种的安全性和免疫原性非劣效性研究。
- 参与者按5剂Essen肌内方案(4周、1个注射部位方案,第0、3、7、14和28天各接种1剂)接种,第0天同时接种HRIG。
- 第0、14、28和42天评估狂犬病病毒中和抗体(RVNA)。
- 非劣效性判定标准为PVRV-NG与HDCV第14天血清阳转率(RVNA滴度≥0.5 IU/mL)差异的95%CI下限高于非劣效界值-5%。
- 每次接种后评估安全性并在整个研究期间监测。
主要发现
- PVRV-NG组与HDCV组第14天血清阳转率差异为-2.8%(95%CI -8.08至4.20),非劣效性未成立。
- 两组第14天血清阳转率均<99%。
- 未发现重大安全性问题,PVRV-NG安全性特征与HDCV相似。
关键数值与推荐
- 非劣效性界值为-5%,以第14天血清阳转率(RVNA滴度≥0.5 IU/mL)差异的95%CI下限高于-5%判定非劣效。
- PVRV-NG组与HDCV组第14天血清阳转率差异为-2.8%(95%CI -8.08至4.20),95%CI下限低于-5%,非劣效性未成立。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A new generation, serum-free, antibiotic-free, purified Vero rabies vaccine (PVRV-NG; Sanofi) has been developed based on the same Pitman-Moore viral strain used for the currently licensed purified Vero cell rabies vaccine (PVRV; Verorab®, Sanofi) and human diploid cell vaccine (HDCV; Imovax® Rabies, Sanofi). PVRV-NG has demonstrated a satisfactory safety profile and induces robust immune responses, with non-inferiority demonstrated versus PVRV when given as a three-dose pre-exposure prophylaxis (PrEP) regimen in healthy children and adults. Here, we evaluated the safety and immunogenic non-inferiority of PVRV-NG compared to HDCV when administered as simulated post-exposure prophylaxis (PEP), with concomitant administration of human rabies immunoglobulin (HRIG), in healthy adults in the USA. Participants were vaccinated according to the 5-dose Essen intramuscular regimen (4-week, 1-injection site regimen, with a single dose given on days 0, 3, 7, 14 and 28) for PEP, with concomitant HRIG administered on day 0. Rabies virus neutralising antibodies (RVNA) were evaluated on days 0, 14, 28 and 42. Non-inferiority of PVRV-NG compared with HDCV was shown if the lower limit of the 95 % confidence interval (CI) for the difference in seroconversion rates (RVNA titers ≥ 0.5 IU/mL on day 14) between PVRV-NG and HDCV was above the non-inferiority margin of -5 %. Safety was evaluated after each vaccination and monitored throughout the study. The difference in seroconversion rate between the PVRV-NG and HDCV groups was -2.8 % (95 % CI, -8.08 to 4.20), indicating that non-inferiority was not demonstrated. The seroconversion rate was < 99 % in both study groups on day 14. There were no major safety concerns identified, and PVRV-NG demonstrated a similar safety profile to HDCV.
引用
- Pichon S, Moureau A, Petit C, et al. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults. Vaccine. 2023. PMID: 38105138. doi:10.1016/j.vaccine.2023.11.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。